Gemcitabine and cisplatin are commonly used in combination together, and since Ets-1 is involved in cisplatin resistance, further study of the validity of pre-treatment of GSH-depleting agents with gemcitabine and cisplatin combination therapy for ovarian cancer is warranted [8]. The gene discussed is ETS1; the disease is ovarian cancer.